Ketanov (Ketorolac Trometamol)

Ketorolac trometamol works by non‑selectively blocking the cyclooxygenase‑1 and cyclooxygenase‑2 enzymes, which are essential for the production of prostaglandins. By reducing prostaglandin synthesis, the drug diminishes inflammation, lowers the sensitivity of pain receptors, and provides effective analgesia.

The specific dose and frequency of Ketanov are determined by the prescribing clinician based on the patient’s condition, weight, renal function, and overall treatment plan. Healthcare professionals follow local guidelines and product labeling to set an appropriate regimen.

The safety of ketorolac trometamol in pregnancy and lactation has not been definitively established. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the Ketanov product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details (including any cold‑chain requirements), and import documentation.

Ketanov (ketorolac trometamol) is distinguished by its potent analgesic effect, often comparable to opioid analgesics for short‑term use, whereas many other NSAIDs provide milder pain relief. However, its risk profile for gastrointestinal bleeding and renal effects is higher, so it is typically reserved for brief periods and monitored closely.

Ketanov should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from direct sunlight, moisture, and extreme temperature fluctuations. Do not freeze the solution, and keep it out of reach of children.

Ketanov is supplied as a sterile injectable solution for intramuscular injection. The healthcare professional selects an appropriate injection site, typically the gluteal or deltoid muscle, and administers the dose using aseptic technique according to the prescribed regimen.

The most serious risks include severe bleeding, gastrointestinal ulceration or perforation, renal failure, cardiovascular thrombotic events such as myocardial infarction or stroke, and rare but life‑threatening allergic reactions like anaphylaxis. Patients should be monitored closely for signs of these complications.

Ketanov is contraindicated in patients with known hypersensitivity to ketorolac, other NSAIDs, or aspirin; those with active gastrointestinal bleeding or ulcer disease; severe renal impairment; and patients who have recently undergone coronary artery bypass graft surgery. It should also be avoided in individuals at high risk for cardiovascular events unless specifically directed by a physician.